ATRS Antares Pharma Inc.

ATRS LOSS NOTICE: Rosen Law Firm Reminds Antares Pharma, Inc. Investors of Important Deadline in Class Action

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Antares Pharma, Inc. (NASDAQ: ATRS) from December 21, 2016 through October 12, 2017, inclusive (the “Class Period”) of the important December 22, 2017 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Antares investors under the federal securities laws.

To join the Antares class action, go to http://rosenlegal.com/cases-1237.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Antares had provided insufficient data to the U.S. Food and Drug Administration in connection with its New Drug Application for Xyosted; (2) as a result, Antares had overstated the approval prospects for Xyosted; (3) consequently, Antares’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 22, 2017. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1237.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

EN
28/11/2017

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Antares Pharma Inc.

 PRESS RELEASE

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment fo...

Antares Pharma Announces FDA Approval Of TLANDO™, an Oral Treatment for Testosterone Replacement Therapy Commercial launch expected in 2Q 2022 EWING, N.J., March 29, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration granted final approval for TLANDO™ (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”) indicated for conditions associated with a deficiency or absence of endogenous testosterone, or hypogonadism in adult males. Ro...

 PRESS RELEASE

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and...

Antares Pharma Reports Fourth Quarter and Full-Year 2021 Financial and Operating Results Full-Year 2021 Revenue Increased 23% Year-Over-Year to $184.0 Million Full-Year 2021 Net Income of $46.3 Million, or $0.26 Per Diluted Earnings Per Share Full-Year 2021 Adjusted EBITDA of $39.2 Million 2022 Revenue Guidance Range of $200 to $220 Million EWING, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the fourth quarter ended December 31, 2021 with record reven...

 PRESS RELEASE

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conferen...

Antares Pharma to Present at the Cowen 42nd Annual Healthcare Conference EWING, N.J., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Cowen 42nd Annual Healthcare Conference being held on March 7-9, 2022. Details of the presentation are as follows: Event:  Cowen 42nd Annual Healthcare ConferenceFormat:  Fireside Chat and 1x1 MeetingsPresentation Date: Tuesday, March ...

 PRESS RELEASE

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial A...

Antares Pharma To Report Fourth Quarter And Full-Year 2021 Financial And Operating Results EWING, N.J., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its fourth quarter and full-year 2021 financial and operating results on Thursday, March 3, 2022, before the market opens. Antares will host a conference call on Thursday, March 3, 2022 at 8:30am ET to discuss the results. The dial-in numbers are (888) 254-3590 for domestic callers and (323) 794-2551 for international callers. The co...

 PRESS RELEASE

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO...

Antares Pharma Announces FDA Acceptance of NDA Resubmission for TLANDO® PDUFA target action date set for March 28, 2022 EWING, N.J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has accepted its New Drug Application (“NDA”) resubmission for TLANDO® (testosterone undecanoate), an oral treatment for testosterone replacement therapy (“TRT”). The FDA designated the NDA as a Class 1 resubmission with a two-month review goal period and set a target a...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch